Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery
The round will fund clinical testing, global hiring and expansion as the company scales its IsoDDE platform and drug candidate pipeline.
- On Wednesday, Isomorphic Labs announced it raised $2.1 billion in Series B funding led by existing investor Thrive Capital, marking a major expansion for the AI-driven drug discovery company.
- Founded in 2021 as a Google DeepMind spin-off, Isomorphic Labs builds on AlphaFold, an AI program that predicts protein structures to accelerate drug design and disease research.
- The funding round includes participation from existing backers Alphabet and Google Ventures, alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund supporting the IsoDDE platform.
- Isomorphic Labs will use the capital to accelerate clinical trials, now expected by end of 2026, while expanding its global team across London, Lausanne, and Cambridge.
- "This funding round is a massive vote of confidence," said CEO Demis Hassabis, while Thrive Capital Founder Joshua Kushner noted the team's conviction has deepened over the past year.
12 Articles
12 Articles
Thrive Capital led the round for the AI drug discovery company.
Alphabet-backed Isomorphic Labs raises $2.1B to accelerate AI-designed drug discovery as clinical trials near - Tech Startups
Drug discovery has long been one of the slowest and most expensive parts of modern medicine. Isomorphic Labs, a drug discovery startup spun out of Google DeepMind, wants artificial intelligence to change that, and investors are betting billions that it can. […] The post Alphabet-backed Isomorphic Labs raises $2.1B to accelerate AI-designed drug discovery as clinical trials near first appeared on Tech Startups.
Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery
May 12 : Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive Capital.The funding round, completed at an undisclosed valuation, also included other existing investors, Google Ventures
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
